Simon Y Kimm, MD
Urology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Eden Medical Center · Stanford Health Care Tri-Valley · Sutter Medical Center, Sacramento · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kimm’s office at (510) 490-1222 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A100005 · Current
Licensed to practise in California · since 2007 · expires 2028-11-30 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$239,364
Medicare paid this office $239,364 for 406 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 292 | $58,669 | $112 |
| Diagnostic exam of bladder and urethra using an endoscope | 57 | $17,536 | $247 |
| New patient visit (45+ min) | 104 | $15,088 | $145 |
| Long return visit (40+ min) | 52 | $12,836 | $157 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 317 | $7,316 | $14 |
See all 16 services
| Return visit (30+ min) | 292 | $58,669 | $112 |
| Diagnostic exam of bladder and urethra using an endoscope | 57 | $17,536 | $247 |
| New patient visit (45+ min) | 104 | $15,088 | $145 |
| Long return visit (40+ min) | 52 | $12,836 | $157 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 317 | $7,316 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $4,524 | $105 |
| Biopsy of prostate gland | 13 | $2,997 | $231 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,617 | $154 |
| Short return visit (20+ min) | 23 | $2,061 | $82 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,994 | $142 |
| Ultrasound measurement of bladder capacity after voiding | 55 | $719 | $12 |
| Imaging of urinary tract following injection of a contrast agent | 14 | $348 | $22 |
| Automated urinalysis test | 83 | $233 | $2 |
| Electronic assessment of bladder emptying | 17 | $193 | $10 |
| Urinalysis, manual test | 18 | $65 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 13 | $27 | None |
Procedures Medicare counted
| Hernia repair (minimally invasive) | 1-10 | None |
| Prostate resection | 16 | More than 72% of doctors who do this |
Who their Medicare patients are
406 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 12% · Women 29% · Also on Medicaid 16% · Health risk score 1.08. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 74% · Coronary heart disease 32% · Cancer 31% · Chronic kidney disease 29% · Diabetes 26% · Atrial fibrillation 19% · Depression 16% · Heart failure 14% · COPD 9% · Dementia 8% · Stroke 4%.
The office billed $994,093, Medicare allowed $311,826 and paid $239,364; for 25,614 services of 71 kinds; $42,281 of it was for drugs given in the office and $197,083 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 406 | 25,614 | 76 | 1.08 | $994,093 | $239,364 |
| 2023 | 387 | 26,465 | 76 | 1.07 | $881,521 | $227,411 |
| 2022 | 393 | 23,731 | 75 | 1.07 | $863,156 | $227,894 |
| 2021 | 389 | 21,440 | 74 | 1.10 | $841,215 | $222,740 |
| 2020 | 398 | 23,027 | 74 | 1.20 | $690,420 | $162,917 |
| 2019 | 469 | 9,223 | 74 | 1.30 | $816,619 | $191,333 |
| 2018 | 382 | 9,294 | 75 | 1.34 | $651,802 | $147,146 |
| 2017 | 325 | 6,424 | 75 | 1.37 | $578,791 | $126,962 |
| 2016 | 333 | 1,549 | 75 | 1.29 | $495,673 | $105,970 |
| 2015 | 255 | 1,218 | 74 | 1.21 | $447,439 | $101,005 |
| 2014 | 116 | 386 | 73 | 1.17 | $131,360 | $30,462 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 262 | $53,264 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 74 | $21,114 | $248 |
| New patient visit (45+ min) | 110 | $15,122 | $137 |
| Long return visit (40+ min) | 39 | $9,297 | $163 |
| Biopsy of prostate gland | 17 | $3,997 | $235 |
| Ultrasound scan of pelvic region through rectum | 27 | $3,967 | $147 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $3,956 | $110 |
| Short return visit (20+ min) | 25 | $2,363 | $74 |
| Ultrasound measurement of bladder capacity after voiding | 107 | $1,252 | $10 |
| Injection of drug or substance under skin or into muscle | 15 | $564 | $14 |
| Automated urinalysis test | 107 | $308 | $2 |
| Urinalysis, manual test | 35 | $123 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 17 | $37 | None |
2022: 13 services
| Return visit (30+ min) | 264 | $54,953 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 64 | $18,672 | $249 |
| New patient visit (45+ min) | 107 | $14,626 | $137 |
| Long return visit (40+ min) | 38 | $8,626 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $6,133 | $92 |
| Telephone medical discussion with physician, 21-30 minutes | 37 | $4,259 | $101 |
| Short return visit (20+ min) | 35 | $3,634 | $85 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,482 | $177 |
| Ultrasound scan of pelvic region through rectum | 15 | $2,219 | $148 |
| Ultrasound measurement of bladder capacity after voiding | 137 | $1,693 | $10 |
| New patient visit (30+ min) | 15 | $1,311 | $87 |
| Injection of drug or substance under skin or into muscle | 15 | $576 | $14 |
| Automated urinalysis test | 123 | $368 | $2 |
2021: 11 services
| Return visit (30+ min) | 275 | $54,184 | $114 |
| Diagnostic exam of bladder and urethra using an endoscope | 75 | $19,253 | $241 |
| New patient visit (45+ min) | 111 | $15,743 | $142 |
| Long return visit (40+ min) | 41 | $9,254 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $3,188 | $94 |
| Ultrasound measurement of bladder capacity after voiding | 211 | $3,002 | $10 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $2,905 | $108 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,917 | $147 |
| Short return visit (20+ min) | 16 | $1,780 | $81 |
| Injection of drug or substance under skin or into muscle | 17 | $655 | $14 |
| Automated urinalysis test | 167 | $484 | $2 |
2020: 13 services
| Return visit (30+ min) | 242 | $35,491 | $90 |
| Diagnostic exam of bladder and urethra using an endoscope | 48 | $12,425 | $211 |
| New patient visit (45+ min) | 92 | $12,299 | $134 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $8,694 | $669 |
| Long return visit (40+ min) | 25 | $4,039 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,872 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,143 | $95 |
| Short return visit (20+ min) | 31 | $2,744 | $62 |
| New patient visit (30+ min) | 29 | $2,522 | $87 |
| Ultrasound measurement of bladder capacity after voiding | 162 | $1,969 | $10 |
| Ultrasound scan of pelvic region through rectum | 11 | $1,601 | $146 |
| Injection of drug or substance under skin or into muscle | 16 | $820 | $14 |
| Automated urinalysis test | 118 | $336 | $2 |
2019: 14 services
| Return visit (30+ min) | 256 | $37,253 | $96 |
| Diagnostic exam of bladder and urethra using an endoscope | 68 | $15,462 | $186 |
| New patient visit (45+ min) | 88 | $11,972 | $136 |
| Short return visit (20+ min) | 111 | $8,668 | $60 |
| Insertion of lower leg neurostimulator electrode | 13 | $7,799 | $130 |
| Long return visit (40+ min) | 31 | $6,335 | $132 |
| New patient visit (30+ min) | 74 | $6,280 | $85 |
| Ultrasound measurement of bladder capacity after voiding | 186 | $3,287 | $13 |
| Biopsy of prostate gland | 13 | $3,051 | $235 |
| Ultrasound scan of pelvic region through rectum | 19 | $2,680 | $128 |
| Simple insertion of temporary bladder tube | 12 | $969 | $57 |
| Injection of drug or substance under skin or into muscle | 22 | $510 | $16 |
| Automated urinalysis test | 132 | $434 | $2 |
| Injection, garamycin, gentamicin, up to 80 mg | 15 | $22 | None |
2018: 10 services
| Return visit (30+ min) | 132 | $19,472 | $94 |
| Short return visit (20+ min) | 179 | $18,161 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 58 | $11,230 | $158 |
| New patient visit (45+ min) | 66 | $9,115 | $138 |
| New patient visit (30+ min) | 91 | $8,542 | $94 |
| Ultrasound measurement of bladder capacity after voiding | 187 | $4,510 | $16 |
| Long return visit (40+ min) | 17 | $2,173 | $128 |
| Ultrasound scan of pelvic region through rectum | 15 | $1,360 | $91 |
| Injection of drug or substance under skin or into muscle | 17 | $668 | $19 |
| Automated urinalysis test | 136 | $518 | $3 |
2017: 11 services
| Return visit (30+ min) | 113 | $16,791 | $90 |
| Short return visit (20+ min) | 146 | $14,254 | $59 |
| New patient visit (45+ min) | 79 | $11,072 | $140 |
| Diagnostic exam of bladder and urethra using an endoscope | 56 | $10,244 | $155 |
| New patient visit (30+ min) | 65 | $5,708 | $88 |
| Ultrasound measurement of bladder capacity after voiding | 189 | $5,117 | $19 |
| Long return visit (40+ min) | 16 | $2,357 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,777 | $89 |
| Ultrasound scan of pelvic region through rectum | 15 | $1,308 | $87 |
| Injection of drug or substance under skin or into muscle | 20 | $871 | $23 |
| Automated urinalysis test | 149 | $592 | $3 |
2016: 9 services
| Return visit (30+ min) | 115 | $13,483 | $88 |
| Short return visit (20+ min) | 143 | $13,338 | $59 |
| New patient visit (45+ min) | 87 | $11,144 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 37 | $8,502 | $181 |
| New patient visit (30+ min) | 69 | $5,881 | $85 |
| Ultrasound measurement of bladder capacity after voiding | 189 | $4,936 | $17 |
| Long return visit (40+ min) | 18 | $3,091 | $129 |
| Automated urinalysis test | 161 | $657 | $3 |
| Injection of drug or substance under skin or into muscle | 11 | $383 | $24 |
2015: 11 services
| New patient visit (45+ min) | 102 | $15,038 | $147 |
| Return visit (30+ min) | 72 | $10,060 | $93 |
| Short return visit (20+ min) | 85 | $9,577 | $64 |
| Diagnostic exam of bladder and urethra using an endoscope | 30 | $5,972 | $193 |
| New patient visit (30+ min) | 64 | $5,732 | $90 |
| Ultrasound measurement of bladder capacity after voiding | 146 | $4,452 | $19 |
| Long return visit (40+ min) | 19 | $3,409 | $126 |
| Injection of drug or substance under skin or into muscle | 12 | $477 | $25 |
| Automated urinalysis test | 98 | $390 | $3 |
| Manual urinalysis test with examination using microscope, automated | 48 | $232 | $4 |
| Urinalysis, manual test | 36 | $140 | $3 |
2014: 10 services
| New patient visit (30+ min) | 50 | $4,712 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 18 | $3,295 | $183 |
| Return visit (30+ min) | 19 | $2,874 | $93 |
| New patient visit (45+ min) | 18 | $2,610 | $145 |
| Short return visit (20+ min) | 27 | $2,325 | $65 |
| Long return visit (40+ min) | 13 | $1,917 | $128 |
| Ultrasound measurement of bladder capacity after voiding | 35 | $925 | $18 |
| Urinalysis, manual test | 27 | $113 | $3 |
| Manual urinalysis test with examination using microscope, automated | 17 | $85 | $4 |
| Automated urinalysis test | 22 | $69 | $3 |
Drugs they prescribed that Part D paid
$136,971
Pharmacies billed $136,971 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (80 of 1,810) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
1,676 generic and 134 brand-name prescriptions · $136,971 in drug cost · 356 antibiotic prescriptions to 130 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 91 | $73,255 | $805 |
| Tamsulosin | 503 | $8,166 | $16 |
| Oxybutynin Chloride Er | 134 | $3,865 | $29 |
| Testosterone | 22 | $3,624 | $165 |
| Finasteride | 192 | $2,983 | $16 |
See all 28 drugs
| Myrbetriq | 91 | $73,255 | $805 |
| Tamsulosin | 503 | $8,166 | $16 |
| Oxybutynin Chloride Er | 134 | $3,865 | $29 |
| Testosterone | 22 | $3,624 | $165 |
| Finasteride | 192 | $2,983 | $16 |
| Cabergoline | 17 | $2,064 | $121 |
| Estradiol | 20 | $1,946 | $97 |
| Silodosin | 30 | $1,904 | $63 |
| Potassium Citrate Er | 22 | $1,718 | $78 |
| Alfuzosin Hcl Er | 92 | $1,698 | $18 |
| Nitrofurantoin | 25 | $1,652 | $66 |
| Nitrofurantoin Mono-Macro | 36 | $1,245 | $35 |
| Solifenacin | 25 | $1,203 | $48 |
| Cefdinir | 59 | $785 | $13 |
| Dutasteride | 14 | $531 | $38 |
| Oxycodone-Acetaminophen | 18 | $489 | $27 |
| Cephalexin | 81 | $424 | $5 |
| Cefpodoxime Proxetil | 11 | $392 | $36 |
| Testosterone Cypionate | 15 | $337 | $22 |
| Hydrocodone-Acetaminophen | 29 | $299 | $10 |
| Terazosin | 20 | $267 | $13 |
| Ciprofloxacin | 53 | $248 | $5 |
| Sulfamethoxazole-Trimethoprim | 64 | $232 | $4 |
| Sildenafil Citrate | 12 | $193 | $16 |
| Oxybutynin Chloride | 19 | $166 | $9 |
| Oxycodone | 13 | $164 | $13 |
| Fluconazole | 11 | $82 | $7 |
| Tramadol | 20 | $61 | $3 |
Year by year
| 2024 | 1,810 | 408 | 4% (80) | 7% | $136,971 |
| 2023 | 1,708 | 377 | 4% (76) | None | $137,541 |
| 2022 | 1,796 | 385 | 6% (113) | None | $142,905 |
| 2021 | 1,854 | 393 | 4% (66) | 9% | $135,590 |
| 2020 | 1,987 | 372 | 3% (60) | None | $125,973 |
| 2019 | 1,647 | 356 | 3% (56) | 11% | $110,641 |
| 2018 | 1,458 | 295 | 3% (50) | None | $101,344 |
| 2017 | 1,159 | 234 | 4% (40) | None | $80,180 |
| 2016 | 895 | 195 | 3% (27) | None | $48,985 |
| 2015 | 409 | 123 | 7% (27) | None | $18,770 |
| 2014 | 133 | 62 | 17% (23) | None | $9,232 |
| 2013 | 41 | 30 | 39% (16) | None | $643 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Myrbetriq | 98 | $66,970 | $683 |
| Tamsulosin | 450 | $11,249 | $25 |
| Oxybutynin Chloride Er | 134 | $4,428 | $33 |
| Trospium Chloride Er | 17 | $4,428 | $260 |
| Potassium Citrate Er | 22 | $3,671 | $167 |
| Finasteride | 189 | $3,068 | $16 |
| Alfuzosin Hcl Er | 77 | $2,638 | $34 |
| Nitrofurantoin Mono-Macro | 61 | $1,865 | $31 |
| Solifenacin | 18 | $1,852 | $103 |
| Estradiol | 15 | $1,610 | $107 |
| Cefdinir | 65 | $1,073 | $17 |
| Nitrofurantoin | 23 | $1,045 | $45 |
| Terazosin | 29 | $891 | $31 |
| Cephalexin | 70 | $523 | $7 |
| Sulfamethoxazole-Trimethoprim | 78 | $422 | $5 |
| Oxycodone-Acetaminophen | 22 | $392 | $18 |
| Testosterone Cypionate | 11 | $336 | $31 |
| Ciprofloxacin | 50 | $309 | $6 |
| Amoxicillin-Clavulanate Potass | 20 | $305 | $15 |
| Hydrocodone-Acetaminophen | 24 | $253 | $11 |
| Oxycodone | 14 | $251 | $18 |
| Fluconazole | 17 | $163 | $10 |
| Tramadol | 15 | $121 | $8 |
| Sildenafil Citrate | 11 | $26 | $2 |
2022: 24 drugs
| Myrbetriq | 77 | $60,230 | $782 |
| Tamsulosin | 427 | $8,805 | $21 |
| Oxybutynin Chloride Er | 141 | $7,215 | $51 |
| Potassium Citrate Er | 27 | $3,971 | $147 |
| Finasteride | 216 | $3,910 | $18 |
| Trospium Chloride Er | 13 | $3,714 | $286 |
| Alfuzosin Hcl Er | 120 | $2,598 | $22 |
| Solifenacin | 28 | $2,592 | $93 |
| Nitrofurantoin Mono-Macro | 63 | $2,212 | $35 |
| Cefdinir | 88 | $1,779 | $20 |
| Nitrofurantoin | 15 | $1,124 | $75 |
| Bicalutamide | 18 | $985 | $55 |
| Terazosin | 20 | $747 | $37 |
| Desmopressin Acetate | 16 | $715 | $45 |
| Hydrocodone-Acetaminophen | 74 | $706 | $10 |
| Ciprofloxacin | 63 | $374 | $6 |
| Oxycodone-Acetaminophen | 15 | $277 | $18 |
| Sulfamethoxazole-Trimethoprim | 60 | $274 | $5 |
| Cephalexin | 46 | $239 | $5 |
| Sildenafil Citrate | 15 | $189 | $13 |
| Amoxicillin-Clavulanate Potass | 18 | $135 | $8 |
| Oxycodone | 12 | $130 | $11 |
| Fluconazole | 12 | $66 | $6 |
| Tramadol | 12 | $35 | $3 |
2021: 26 drugs
| Myrbetriq | 74 | $54,962 | $743 |
| Tamsulosin | 460 | $7,196 | $16 |
| Oxybutynin Chloride Er | 133 | $6,475 | $49 |
| Finasteride | 232 | $4,893 | $21 |
| Nitrofurantoin Mono-Macro | 86 | $4,047 | $47 |
| Potassium Citrate Er | 27 | $3,584 | $133 |
| Solifenacin | 27 | $3,245 | $120 |
| Alfuzosin Hcl Er | 102 | $2,531 | $25 |
| Testosterone | 11 | $2,499 | $227 |
| Fosfomycin Tromethamine | 11 | $2,120 | $193 |
| Dutasteride | 20 | $1,564 | $78 |
| Nitrofurantoin | 16 | $1,155 | $72 |
| Cefdinir | 72 | $1,147 | $16 |
| Terazosin | 18 | $875 | $49 |
| Desmopressin Acetate | 18 | $765 | $43 |
| Testosterone Cypionate | 14 | $623 | $45 |
| Cephalexin | 71 | $583 | $8 |
| Bicalutamide | 13 | $464 | $36 |
| Ciprofloxacin | 87 | $408 | $5 |
| Sulfamethoxazole-Trimethoprim | 57 | $222 | $4 |
| Hydrocodone-Acetaminophen | 29 | $213 | $7 |
| Amoxicillin-Clavulanate Potass | 15 | $162 | $11 |
| Gabapentin | 13 | $132 | $10 |
| Sildenafil Citrate | 11 | $98 | $9 |
| Tadalafil | 11 | $63 | $6 |
| Tramadol | 16 | $61 | $4 |
2020: 28 drugs
| Myrbetriq | 58 | $40,407 | $697 |
| Oxybutynin Chloride Er | 164 | $7,898 | $48 |
| Tamsulosin | 481 | $7,423 | $15 |
| Finasteride | 259 | $4,905 | $19 |
| Nitrofurantoin Mono-Macro | 86 | $4,687 | $54 |
| Alfuzosin Hcl Er | 136 | $4,358 | $32 |
| Testosterone | 15 | $3,694 | $246 |
| Solifenacin | 24 | $3,189 | $133 |
| Potassium Citrate Er | 26 | $2,386 | $92 |
| Dutasteride | 26 | $2,114 | $81 |
| Nitrofurantoin | 46 | $2,087 | $45 |
| Cephalexin | 89 | $1,027 | $12 |
| Oxybutynin Chloride | 27 | $860 | $32 |
| Cefdinir | 54 | $792 | $15 |
| Estradiol | 11 | $695 | $63 |
| Terazosin | 16 | $642 | $40 |
| Bicalutamide | 19 | $619 | $33 |
| Doxycycline Hyclate | 11 | $593 | $54 |
| Testosterone Cypionate | 16 | $575 | $36 |
| Pentoxifylline | 12 | $523 | $44 |
| Doxazosin Mesylate | 26 | $474 | $18 |
| Ciprofloxacin | 58 | $357 | $6 |
| Sulfamethoxazole-Trimethoprim | 67 | $265 | $4 |
| Hydrocodone-Acetaminophen | 27 | $169 | $6 |
| Gabapentin | 12 | $150 | $13 |
| Fluconazole | 11 | $127 | $12 |
| Tramadol | 26 | $65 | $2 |
| Naproxen | 13 | $54 | $4 |
2019: 23 drugs
| Myrbetriq | 65 | $35,930 | $553 |
| Vesicare | 14 | $8,446 | $603 |
| Oxybutynin Chloride Er | 139 | $6,748 | $49 |
| Tamsulosin | 416 | $6,567 | $16 |
| Finasteride | 164 | $4,020 | $25 |
| Alfuzosin Hcl Er | 138 | $3,621 | $26 |
| Tolterodine Tartrate Er | 20 | $2,888 | $144 |
| Potassium Citrate Er | 32 | $2,822 | $88 |
| Nitrofurantoin Mono-Macro | 63 | $2,815 | $45 |
| Dutasteride | 28 | $2,125 | $76 |
| Nitrofurantoin | 37 | $1,859 | $50 |
| Oxybutynin Chloride | 27 | $697 | $26 |
| Cephalexin | 79 | $606 | $8 |
| Testosterone Cypionate | 11 | $596 | $54 |
| Desmopressin Acetate | 13 | $587 | $45 |
| Ciprofloxacin | 73 | $529 | $7 |
| Terazosin | 15 | $501 | $33 |
| Doxazosin Mesylate | 18 | $409 | $23 |
| Sulfamethoxazole-Trimethoprim | 65 | $381 | $6 |
| Gabapentin | 14 | $291 | $21 |
| Bicalutamide | 15 | $261 | $17 |
| Hydrocodone-Acetaminophen | 23 | $131 | $6 |
| Tramadol | 31 | $82 | $3 |
2018: 22 drugs
| Myrbetriq | 70 | $31,327 | $448 |
| Vesicare | 39 | $19,848 | $509 |
| Oxybutynin Chloride Er | 134 | $6,689 | $50 |
| Tamsulosin | 339 | $5,584 | $16 |
| Tolterodine Tartrate Er | 25 | $3,666 | $147 |
| Alfuzosin Hcl Er | 156 | $3,241 | $21 |
| Finasteride | 158 | $3,078 | $19 |
| Monurol | 11 | $2,125 | $193 |
| Potassium Citrate Er | 22 | $1,554 | $71 |
| Dutasteride | 22 | $1,483 | $67 |
| Nitrofurantoin Mono-Macro | 37 | $1,319 | $36 |
| Nitrofurantoin | 24 | $1,196 | $50 |
| Cephalexin | 69 | $570 | $8 |
| Cabergoline | 11 | $386 | $35 |
| Testosterone Cypionate | 16 | $338 | $21 |
| Ciprofloxacin | 62 | $317 | $5 |
| Amitriptyline | 13 | $295 | $23 |
| Bicalutamide | 18 | $276 | $15 |
| Terazosin | 13 | $267 | $21 |
| Sulfamethoxazole-Trimethoprim | 55 | $255 | $5 |
| Hydrocodone-Acetaminophen | 22 | $147 | $7 |
| Tramadol | 17 | $27 | $2 |
2017: 22 drugs
| Myrbetriq | 53 | $25,090 | $473 |
| Vesicare | 27 | $13,695 | $507 |
| Oxybutynin Chloride Er | 163 | $6,601 | $40 |
| Cialis | 12 | $5,474 | $456 |
| Tamsulosin | 238 | $4,883 | $21 |
| Tolterodine Tartrate Er | 24 | $3,970 | $165 |
| Finasteride | 152 | $2,586 | $17 |
| Dutasteride | 18 | $2,149 | $119 |
| Alfuzosin Hcl Er | 109 | $2,010 | $18 |
| Monurol | 13 | $1,746 | $134 |
| Nitrofurantoin Mono-Macro | 31 | $1,503 | $48 |
| Nitrofurantoin | 15 | $847 | $56 |
| Oxybutynin Chloride | 11 | $286 | $26 |
| Cephalexin | 39 | $282 | $7 |
| Terazosin | 11 | $253 | $23 |
| Bicalutamide | 14 | $226 | $16 |
| Amitriptyline | 14 | $183 | $13 |
| Trimethoprim | 11 | $162 | $15 |
| Ciprofloxacin | 31 | $136 | $4 |
| Sulfamethoxazole-Trimethoprim | 35 | $115 | $3 |
| Hydrocodone-Acetaminophen | 23 | $108 | $5 |
| Testosterone Cypionate | 13 | $78 | $6 |
2016: 14 drugs
| Vesicare | 35 | $11,351 | $324 |
| Myrbetriq | 19 | $6,007 | $316 |
| Oxybutynin Chloride Er | 113 | $5,620 | $50 |
| Cialis | 16 | $4,547 | $284 |
| Tamsulosin | 179 | $4,449 | $25 |
| Finasteride | 164 | $2,296 | $14 |
| Alfuzosin Hcl Er | 82 | $1,019 | $12 |
| Nitrofurantoin | 33 | $997 | $30 |
| Nitrofurantoin Mono-Macro | 18 | $694 | $39 |
| Cephalexin | 41 | $356 | $9 |
| Terazosin | 19 | $232 | $12 |
| Hydrocodone-Acetaminophen | 18 | $146 | $8 |
| Sulfamethoxazole-Trimethoprim | 35 | $143 | $4 |
| Ciprofloxacin | 19 | $94 | $5 |
2015: 10 drugs
| Premarin | 13 | $3,677 | $283 |
| Vesicare | 13 | $3,646 | $280 |
| Oxybutynin Chloride Er | 41 | $1,966 | $48 |
| Tamsulosin | 44 | $896 | $20 |
| Finasteride | 75 | $694 | $9 |
| Nitrofurantoin | 24 | $681 | $28 |
| Nystop | 11 | $439 | $40 |
| Cephalexin | 33 | $344 | $10 |
| Sulfamethoxazole-Trimethoprim | 35 | $163 | $5 |
| Ciprofloxacin | 27 | $123 | $5 |
2014: 4 drugs
| Finasteride | 23 | $252 | $11 |
| Tamsulosin | 19 | $235 | $12 |
| Hydrocodone-Acetaminophen | 18 | $125 | $7 |
| Ciprofloxacin | 12 | $41 | $3 |
2013: 1 drug
| Hydrocodone-Acetaminophen | 11 | $91 | $8 |
Money from drug and device companies
$243 in 2025
| 2025 | 3 | 5 | None | $243 |
| 2021 | 2 | 2 | None | $119 |
| 2020 | 2 | 2 | None | $56 |
| 2019 | 3 | 4 | None | $217 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ferring Pharmaceuticals | Adstiladrin | $158 | 3 payments
|
| Ambu | None | $50 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $35 | 1 payment
|
See all 5 published payments
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-13 | Imfinzi | $35 |
| Ferring Pharmaceuticals | Meals · 2025-07-29 | Adstiladrin | $27 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $116 |
| Ferring Pharmaceuticals | Meals · 2025-02-21 | Adstiladrin | $15 |
| Ambu | Meals · 2025-02-05 | None | $50 |
See earlier years (2021, 2020, 2019)
2021: $119
| Astellas Pharma US | None | $100 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $19 | 1 payment
|
2020: $56
| Ethicon US | Vistaseal | $38 | 1 payment
|
| Allergan | Botox | $19 | 1 payment
|
2019: $217
| Endo Pharmaceuticals | Xiaflex | $100 | 1 payment
|
| Pfizer | Xtandi | $78 | 1 payment
|
| Allergan | Botox | $39 | 2 payments
|
Professional record
- NPI
- 1952598518
- Licence
- CA A100005, NY 2602321California A100005: Current · expires 2028-11-30
- Trained
- Northwestern University Feinberg Medical School, 2005
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-09-27
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4000 Dublin Blvd, Dublin, CA, 94568 · 3200 Kearney St, Fremont, CA, 94538